Compare MRTN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | DRTS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1994 | 2021 |
| Metric | MRTN | DRTS |
|---|---|---|
| Price | $13.78 | $14.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 418.5K | ★ 585.4K |
| Earning Date | 04-23-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,131,455,000.00 | N/A |
| Revenue This Year | $2.23 | N/A |
| Revenue Next Year | $8.59 | $699.98 |
| P/E Ratio | $175.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $3.43 |
| 52 Week High | $18.48 | $15.17 |
| Indicator | MRTN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 55.24 |
| Support Level | $13.60 | $13.65 |
| Resistance Level | $13.95 | $14.93 |
| Average True Range (ATR) | 0.34 | 0.63 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 13.89 | 57.57 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.